Sanofi SNY

What this company does

Sanofi sells prescription drugs primarily to wholesale drug distributors, independent and chain retail drug outlets, hospitals, clinics, managed-care organizations and government institutions. It manufactures the majority of its products in-house, through a production process with three principal stages: the manufacture of active ingredients, the transformation of those ingredients into drug products or vaccines, and the final packaging. The company has business operations in approximately 60 countries, and its products are available in more than 160 countries. Expenditures on research and development amounted to 7,842 million euros in 2025, approximately 18.0% of net sales. Its activities are organized around the categories of Immunology, Rare Diseases, Neurology, Oncology, Other Medicines and Vaccines, within the Biopharma operating segment. In immunology, Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 pathways. Sanofi produces and markets several distinct influenza vaccines that are sold globally. The Vaccines business produces vaccines at various sites, with the main locations situated in France, the US, Canada, India, Mexico and China.

Written from the business description in Sanofi's annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.